PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

PRCT 10.09.2024

Full Press ReleaseSEC FilingsOur PRCT Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - 36th Annual Piper Sandler Healthcare Conference
  • 11.26.2024 - PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
  • 10.30.2024 - PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

Recent Filings

  • 12.06.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.04.2024 - 144 Report of proposed sale of securities
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) --PROCEPT BioRobotics®Corporation(the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

  • Webcast link for interested listeners:
    • https://edge.media-server.com/mmc/p/yhamkcsz
  • Dial-in registration for sell-side research analysts:
    • https://register.vevent.com/register/BI271ff7de75a342d8941d642d1900ba40

Live audio of the webcast will be available on the “Investors” section of the Company’s website at:https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at:https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM®and HYDROSTM Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@PROCEPT-BioRobotics.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com